[Advanced prostate cancer: sequence of androgen receptor-targeted substances and chemotherapy determines long-term survival].

[1]  F. Saad,et al.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[2]  T. Tammela,et al.  Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .

[3]  F. Saad,et al.  Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). , 2020 .

[4]  J. Carles,et al.  Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study. , 2020 .

[5]  M. Gleave,et al.  Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. , 2019, The Lancet. Oncology.

[6]  O. Sartor,et al.  Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA , 2019, Annals of Oncology.

[7]  N. Agarwal,et al.  PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations , 2019, Annals of Oncology.

[8]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[9]  H. Gelderblom,et al.  Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. , 2019, Clinical genitourinary cancer.

[10]  M. Sydes,et al.  Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[13]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[14]  S. Culine,et al.  Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC). , 2019, Journal of Clinical Oncology.

[15]  F. Saad,et al.  Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[16]  D. Spaeth,et al.  Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry. , 2019, Journal of Clinical Oncology.

[17]  A. Villers,et al.  Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. , 2019, Journal of Clinical Oncology.

[18]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[19]  J. Carles,et al.  An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA) , 2018, BJU international.

[20]  A. Armstrong,et al.  Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. , 2019, European urology oncology.

[21]  E. Esteban,et al.  Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents , 2018, Clinical genitourinary cancer.

[22]  M. Borre,et al.  Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[24]  A. Fourrier-Réglat,et al.  Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort. , 2018 .

[25]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[26]  A. Ravaud,et al.  Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. , 2017, European urology.

[27]  D. Betticher,et al.  Quality of Life in Second‐Line Treatment of Metastatic Castration‐Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry , 2017, Clinical genitourinary cancer.

[28]  J. Carles,et al.  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[30]  T. Ecke,et al.  Quality of life and pain relief in men with metastatic castration‐resistant prostate cancer on cabazitaxel: the non‐interventional ‘QoLiTime’ study , 2017, BJU international.

[31]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[33]  G. Tortora,et al.  Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. , 2015, Critical reviews in oncology/hematology.

[34]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[35]  C. V. von Klot,et al.  Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. , 2015, European urology.

[36]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  A. Bergman,et al.  Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment , 2014, Cancer.

[38]  M. Kuczyk,et al.  Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer , 2014, Advances in Therapy.

[39]  M. Cronauer,et al.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. , 2014, European urology.

[40]  J. Bono,et al.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.

[41]  F. Saad,et al.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Armstrong,et al.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Bono,et al.  Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  B. Tombal,et al.  Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey. , 2013, European journal of cancer care.